Yhdysvallat - englanti - NLM (National Library of Medicine)

physicians total care, inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), prednisolone acetate (unii: 8b2807733d) (prednisolone - unii:9phq9y1olm) - sulfacetamide sodium 100 mg in 1 ml - a steroid/anti-infective combination is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular antibacterial drug in this product is active against the following common bacterial eye pa

Yhdysvallat - englanti - NLM (National Library of Medicine)

physicians total care, inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), prednisolone acetate (unii: 8b2807733d) (prednisolone - unii:9phq9y1olm) - sulfacetamide sodium 100 mg in 1 g - blephamide® ophthalmic ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular antibacterial drug in this product is active against the following common bacterial eye pathoge

Kanada - englanti - Health Canada

pharma stulln inc. - sulfacetamide sodium; prednisolone acetate - suspension - 10%; 0.5% - sulfacetamide sodium 10%; prednisolone acetate 0.5% - sulfonamides

Yhdysvallat - englanti - NLM (National Library of Medicine)

allergan, inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), prednisolone acetate (unii: 8b2807733d) (prednisolone - unii:9phq9y1olm) - blephamide ®   ophthalmic suspension is a steroid/anti-infective combination drug indicated for steroid- responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular antibacterial drug in this product is active ag

Yhdysvallat - englanti - NLM (National Library of Medicine)

bi-coastal pharma international llc - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide sodium 90 mg in 1 g - sulfacetamide sodium and sulfur wash is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. sulfacetamide sodium and sulfur wash is contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation. sulfacetamide sodium and sulfur wash is not to be used by patients with kidney disease.

Yhdysvallat - englanti - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium 100 mg in 1 ml - sulfacetamide sodium ophthalmic solution usp, 10% is indicated for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma: escherichia coli, staphylococcus aureus, streptococcus pneumoniae, streptococcus (viridans group), haemophilus influenzae, klebsiella species, and enterobacter species. topically applied sulfonamides do not provide adequate coverage against neisseria species, serratia marcescens and pseudomonas aeruginosa . a significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. sulfacetamide sodium ophthalmic solution is contraindicated in individuals who have a hypersensitivity to sulfonamides or to any ingredient of the preparation.

Yhdysvallat - englanti - NLM (National Library of Medicine)

bausch & lomb incorporated - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium 100 mg in 1 ml - sulfacetamide sodium ophthalmic solution usp, 10% is indicated for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma: escherichia coli, staphylococcus aureus, streptococcus pneumoniae, streptococcus  (viridans group), haemophilus influenzae, klebsiella  species, and enterobacter  species. topically applied sulfonamides do not provide adequate coverage against neisseria  species, serratia marcescens  and pseudomonas aeruginosa . a significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. sulfacetamide sodium ophthalmic solution usp, 10% is contraindicated in individuals who have a hypersensitivity to sulfonamides or to any ingredient of the preparation.

Yhdysvallat - englanti - NLM (National Library of Medicine)

h.j. harkins company, inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium 100 mg in 1 ml - sulfacetamide sodium ophthalmic solution usp, 10% is indicated for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma: escherichia coli, staphylococcus aureus, streptococcus pneumoniae, streptococcus (viridans group), haemophilus influenzae, klebsiella species, and enterobacter species. topically applied sulfonamides do not provide adequate coverage against neisseria species, serratia marcescens and pseudomonas aeruginosa . a significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. sulfacetamide sodium ophthalmic solution is contraindicated in individuals who have a hypersensitivity to sulfonamides or to any ingredient of the preparation.

Yhdysvallat - englanti - NLM (National Library of Medicine)

stat rx usa llc - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium 100 mg in 1 ml - sulfacetamide sodium ophthalmic solution usp, 10% is indicated for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma: escherichia coli, staphylococcus aureus, streptococcus pneumoniae, streptococcus (viridans group), haemophilus influenzae, klebsiella species, and enterobacter species. topically applied sulfonamides do not provide adequate coverage against neisseria species, serratia marcescens and pseudomonas aeruginosa. a significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. sulfacetamide sodium ophthalmic solution is contraindicated in individuals who have a hypersensitivity to sulfonamides or to any ingredient of the preparation.

Yhdysvallat - englanti - NLM (National Library of Medicine)

keltman pharmaceuticals inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium 100 mg in 1 ml - sulfacetamide sodium ophthalmic solution usp, 10% is indicated for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma: escherichia coli, staphylococcus aureus, streptococcus pneumoniae, streptococcus (viridans group), haemophilus influenzae, klebsiella species, and enterobacter species. topically applied sulfonamides do not provide adequate coverage against neisseria species, serratia marcescens and pseudomonas aeruginosa. a significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. sulfacetamide sodium ophthalmic solution is contraindicated in individuals who have a hypersensitivity to sulfonamides or to any ingredient of the preparation.